CN103403543B9 - 结肠癌基因表达签名及使用方法 - Google Patents
结肠癌基因表达签名及使用方法 Download PDFInfo
- Publication number
- CN103403543B9 CN103403543B9 CN201280010123.2A CN201280010123A CN103403543B9 CN 103403543 B9 CN103403543 B9 CN 103403543B9 CN 201280010123 A CN201280010123 A CN 201280010123A CN 103403543 B9 CN103403543 B9 CN 103403543B9
- Authority
- CN
- China
- Prior art keywords
- colon cancer
- expression
- nucleic acid
- sample
- transcript
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 250
- 230000014509 gene expression Effects 0.000 title claims abstract description 244
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 217
- 238000000034 method Methods 0.000 title claims abstract description 183
- 108700019961 Neoplasm Genes Proteins 0.000 title abstract description 5
- 102000048850 Neoplasm Genes Human genes 0.000 title abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 141
- 238000004393 prognosis Methods 0.000 claims abstract description 100
- 201000011510 cancer Diseases 0.000 claims abstract description 80
- 210000001072 colon Anatomy 0.000 claims abstract description 34
- 238000002493 microarray Methods 0.000 claims abstract description 25
- 238000011226 adjuvant chemotherapy Methods 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 130
- 150000007523 nucleic acids Chemical class 0.000 claims description 127
- 102000039446 nucleic acids Human genes 0.000 claims description 122
- 108020004707 nucleic acids Proteins 0.000 claims description 122
- 238000001514 detection method Methods 0.000 claims description 54
- 238000011282 treatment Methods 0.000 claims description 34
- 238000001228 spectrum Methods 0.000 claims description 26
- 230000004044 response Effects 0.000 claims description 25
- 238000003745 diagnosis Methods 0.000 claims description 24
- 238000013518 transcription Methods 0.000 claims description 24
- 230000035897 transcription Effects 0.000 claims description 24
- 239000002299 complementary DNA Substances 0.000 claims description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 18
- 230000004083 survival effect Effects 0.000 claims description 18
- 230000007774 longterm Effects 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- -1 PTK2 Proteins 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims description 9
- 108700010013 HMGB1 Proteins 0.000 claims description 9
- 101150021904 HMGB1 gene Proteins 0.000 claims description 9
- 102100037907 High mobility group protein B1 Human genes 0.000 claims description 9
- 238000001574 biopsy Methods 0.000 claims description 8
- 201000002313 intestinal cancer Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 7
- 238000010195 expression analysis Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 claims 16
- 102100032219 Cathepsin D Human genes 0.000 claims 16
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 claims 16
- 108010055323 EphB4 Receptor Proteins 0.000 claims 16
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims 16
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 claims 16
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 claims 16
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 claims 16
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 claims 16
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 16
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims 16
- 102100035683 Axin-2 Human genes 0.000 claims 8
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 8
- 102100031168 CCN family member 2 Human genes 0.000 claims 8
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 8
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 claims 8
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 8
- 102100033940 Ephrin-A3 Human genes 0.000 claims 8
- 108010009307 Forkhead Box Protein O3 Proteins 0.000 claims 8
- 102100035421 Forkhead box protein O3 Human genes 0.000 claims 8
- 108700031843 GRB7 Adaptor Proteins 0.000 claims 8
- 101150052409 GRB7 gene Proteins 0.000 claims 8
- 102100033107 Growth factor receptor-bound protein 7 Human genes 0.000 claims 8
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 claims 8
- 101000874569 Homo sapiens Axin-2 Proteins 0.000 claims 8
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims 8
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 8
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 8
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 8
- 101000925241 Homo sapiens Ephrin-A3 Proteins 0.000 claims 8
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 claims 8
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 8
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 8
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 8
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims 8
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 8
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 8
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims 8
- 101001139126 Homo sapiens Krueppel-like factor 6 Proteins 0.000 claims 8
- 101000896484 Homo sapiens Mitotic checkpoint protein BUB3 Proteins 0.000 claims 8
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims 8
- 101000591187 Homo sapiens Notch homolog 2 N-terminal-like protein A Proteins 0.000 claims 8
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 claims 8
- 101000639763 Homo sapiens Regulator of telomere elongation helicase 1 Proteins 0.000 claims 8
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 claims 8
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 claims 8
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 8
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 8
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 8
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims 8
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims 8
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 8
- 102100020679 Krueppel-like factor 6 Human genes 0.000 claims 8
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 8
- 102100021718 Mitotic checkpoint protein BUB3 Human genes 0.000 claims 8
- 102100034263 Mucin-2 Human genes 0.000 claims 8
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 claims 8
- 102100034093 Notch homolog 2 N-terminal-like protein A Human genes 0.000 claims 8
- 108010029751 Notch2 Receptor Proteins 0.000 claims 8
- 102100034911 Pyruvate kinase PKM Human genes 0.000 claims 8
- 102100038914 RalA-binding protein 1 Human genes 0.000 claims 8
- 101150041852 Ralbp1 gene Proteins 0.000 claims 8
- 102100034469 Regulator of telomere elongation helicase 1 Human genes 0.000 claims 8
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims 8
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 claims 8
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 claims 8
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 claims 8
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 8
- 108010045815 superoxide dismutase 2 Proteins 0.000 claims 8
- 239000000032 diagnostic agent Substances 0.000 claims 6
- 229940039227 diagnostic agent Drugs 0.000 claims 6
- 101150010856 CRT gene Proteins 0.000 claims 1
- 210000004247 hand Anatomy 0.000 claims 1
- 230000004547 gene signature Effects 0.000 abstract description 9
- 238000002271 resection Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 275
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 105
- 210000001519 tissue Anatomy 0.000 description 92
- 239000002773 nucleotide Substances 0.000 description 51
- 125000003729 nucleotide group Chemical group 0.000 description 50
- 108020004999 messenger RNA Proteins 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 48
- 238000004458 analytical method Methods 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 35
- 108091034117 Oligonucleotide Proteins 0.000 description 34
- 238000012549 training Methods 0.000 description 34
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 32
- 238000009396 hybridization Methods 0.000 description 32
- 238000003752 polymerase chain reaction Methods 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 31
- 230000008859 change Effects 0.000 description 30
- 238000011160 research Methods 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- 230000000295 complement effect Effects 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 26
- 238000005259 measurement Methods 0.000 description 26
- 239000000463 material Substances 0.000 description 24
- 230000000875 corresponding effect Effects 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 22
- 230000008569 process Effects 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 238000003908 quality control method Methods 0.000 description 20
- 239000007787 solid Substances 0.000 description 18
- 230000003321 amplification Effects 0.000 description 17
- 238000002790 cross-validation Methods 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 16
- 238000002372 labelling Methods 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 108091006298 SLC2A3 Proteins 0.000 description 12
- 102100022722 Solute carrier family 2, facilitated glucose transporter member 3 Human genes 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 238000007901 in situ hybridization Methods 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 11
- 238000013461 design Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 102100033887 Arylsulfatase D Human genes 0.000 description 10
- 101000925559 Homo sapiens Arylsulfatase D Proteins 0.000 description 10
- 238000000018 DNA microarray Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 8
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 8
- 101000836994 Homo sapiens Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 8
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 8
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000007689 inspection Methods 0.000 description 8
- 238000012775 microarray technology Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 description 7
- 101001120760 Homo sapiens Olfactomedin-4 Proteins 0.000 description 7
- 101000692683 Homo sapiens RING finger protein 39 Proteins 0.000 description 7
- 102100022497 Mucin-3A Human genes 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 102100026071 Olfactomedin-4 Human genes 0.000 description 7
- 102100026465 RING finger protein 39 Human genes 0.000 description 7
- 238000003499 nucleic acid array Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- 102100032424 B-cell CLL/lymphoma 9-like protein Human genes 0.000 description 6
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 6
- 101000798491 Homo sapiens B-cell CLL/lymphoma 9-like protein Proteins 0.000 description 6
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 6
- 101000913082 Homo sapiens IgGFc-binding protein Proteins 0.000 description 6
- 101000609959 Homo sapiens Protein piccolo Proteins 0.000 description 6
- 102100026103 IgGFc-binding protein Human genes 0.000 description 6
- 102100039154 Protein piccolo Human genes 0.000 description 6
- 108091006302 SLC2A14 Proteins 0.000 description 6
- 102100039672 Solute carrier family 2, facilitated glucose transporter member 14 Human genes 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 101001064542 Homo sapiens Liprin-beta-1 Proteins 0.000 description 4
- 101000826406 Homo sapiens Sulfotransferase 1C2 Proteins 0.000 description 4
- 101000585332 Homo sapiens Sulfotransferase 1C4 Proteins 0.000 description 4
- 102100031961 Liprin-beta-1 Human genes 0.000 description 4
- 102100023985 Sulfotransferase 1C2 Human genes 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 238000002869 basic local alignment search tool Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 229920000620 organic polymer Polymers 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000011127 biaxially oriented polypropylene Substances 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 201000010989 colorectal carcinoma Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000003909 pattern recognition Methods 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000212384 Bifora Species 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 241000218636 Thuja Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004176 ammonification Methods 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 229920006378 biaxially oriented polypropylene Polymers 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007850 in situ PCR Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 238000005497 microtitration Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000003068 pathway analysis Methods 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000004557 prognostic gene signature Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013456 study Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- PZWQOGNTADJZGH-SNAWJCMRSA-N (2e)-2-methylpenta-2,4-dienoic acid Chemical compound OC(=O)C(/C)=C/C=C PZWQOGNTADJZGH-SNAWJCMRSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 206010001167 Adenocarcinoma of colon Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 208000032818 Microsatellite Instability Diseases 0.000 description 1
- NRGONRDRXCPMIC-GDKBPFBDSA-N N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CC(C=O)C(O)=O)C(O)=O)C=C1 Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CC(C=O)C(O)=O)C(O)=O)C=C1 NRGONRDRXCPMIC-GDKBPFBDSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000008481 normal tissue growth Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000001259 photo etching Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229950000845 politef Drugs 0.000 description 1
- 229920001596 poly (chlorostyrenes) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161435922P | 2011-01-25 | 2011-01-25 | |
| US61/435,922 | 2011-01-25 | ||
| PCT/US2012/022594 WO2012103250A2 (en) | 2011-01-25 | 2012-01-25 | Colon cancer gene expression signatures and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| CN103403543A CN103403543A (zh) | 2013-11-20 |
| CN103403543B CN103403543B (zh) | 2016-11-09 |
| CN103403543B9 true CN103403543B9 (zh) | 2017-05-17 |
Family
ID=46581385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280010123.2A Expired - Fee Related CN103403543B9 (zh) | 2011-01-25 | 2012-01-25 | 结肠癌基因表达签名及使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10196691B2 (enExample) |
| EP (1) | EP2668296B1 (enExample) |
| JP (1) | JP2014509189A (enExample) |
| KR (1) | KR20140006898A (enExample) |
| CN (1) | CN103403543B9 (enExample) |
| AU (1) | AU2012209074A1 (enExample) |
| BR (1) | BR112013018924A2 (enExample) |
| CA (1) | CA2825218A1 (enExample) |
| EA (1) | EA201391074A1 (enExample) |
| IL (1) | IL227643A0 (enExample) |
| MX (1) | MX2013008367A (enExample) |
| SG (1) | SG192108A1 (enExample) |
| WO (1) | WO2012103250A2 (enExample) |
| ZA (1) | ZA201305024B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2556171E (pt) | 2010-04-05 | 2015-12-21 | Prognosys Biosciences Inc | Ensaios biológicos codificados espacialmente |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| US20130074201A1 (en) * | 2011-09-16 | 2013-03-21 | The Johns Hopkins University | Cancer-specific genetic rearrangements |
| DK3511423T4 (da) * | 2012-10-17 | 2024-07-29 | Spatial Transcriptomics Ab | Fremgangsmåder og produkt til optimering af lokaliseret eller rumlig detektion af genekspression i en vævsprøve |
| EP4234716A3 (en) | 2013-06-25 | 2023-12-06 | Prognosys Biosciences, Inc. | Methods for determining spatial patterns of biological targets in a sample |
| US9652722B1 (en) * | 2013-12-05 | 2017-05-16 | The Mathworks, Inc. | Methods and systems for robust supervised machine learning |
| WO2015121465A1 (en) * | 2014-02-17 | 2015-08-20 | Ventana Medical Systems, Inc. | G-alpha, interacting vesicle associated protein (giv) as a predictive marker in stage ii colorectal cancer |
| CN106460047B (zh) * | 2014-04-10 | 2019-11-26 | 比奥马卡尔技术有限公司 | 用于鉴定癌前结肠直肠息肉和结肠直肠癌的方法及试剂盒 |
| EP4119677B1 (en) | 2015-04-10 | 2023-06-28 | Spatial Transcriptomics AB | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
| CN108020672A (zh) * | 2016-11-03 | 2018-05-11 | 中国医学科学院基础医学研究所 | 检测rhbdd1蛋白的elisa方法及试剂盒 |
| WO2018107023A1 (en) * | 2016-12-08 | 2018-06-14 | Dana-Farber Cancer Institute, Inc. | Metabolic profiling of fixed samples |
| CN107158388B (zh) * | 2017-07-11 | 2021-03-23 | 上海市第一人民医院 | MIIP pS303阻断剂在制备抗肿瘤药物中的应用 |
| EP3743534B1 (en) * | 2018-01-22 | 2022-03-23 | Liquid Biopsy Research LLC | Methods for colon cancer detection and treatment monitoring |
| AU2019252672B2 (en) * | 2018-04-12 | 2025-08-14 | Board Of Regents, The University Of Texas System | Biomarker for detecting cancer |
| JP2020028278A (ja) * | 2018-08-24 | 2020-02-27 | 国立大学法人九州大学 | 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法 |
| CN111321220A (zh) * | 2018-12-14 | 2020-06-23 | 中国医学科学院肿瘤医院 | 用于检测直肠癌放化疗敏感性的组合物、微阵列和计算机系统 |
| CN110079607B (zh) * | 2019-04-04 | 2022-08-02 | 陕西师范大学 | 一种引物组、检测血液样品种属的方法及应用 |
| EP3976820A1 (en) | 2019-05-30 | 2022-04-06 | 10X Genomics, Inc. | Methods of detecting spatial heterogeneity of a biological sample |
| WO2021247568A1 (en) | 2020-06-02 | 2021-12-09 | 10X Genomics, Inc. | Spatial trancriptomics for antigen-receptors |
| EP4025692A2 (en) | 2020-06-02 | 2022-07-13 | 10X Genomics, Inc. | Nucleic acid library methods |
| ES2981265T3 (es) | 2020-06-08 | 2024-10-08 | 10X Genomics Inc | Métodos para determinar un margen quirúrgico y métodos de uso del mismo |
| WO2022002873A1 (en) * | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| CN111951883A (zh) * | 2020-08-04 | 2020-11-17 | 广东省第二人民医院（广东省卫生应急医院） | 一种特征mRNA表达谱组合及结肠癌早期预测方法 |
| CN115786518A (zh) * | 2022-11-29 | 2023-03-14 | 广东医科大学附属医院 | 嗅素结构域家族蛋白4（olfm4）在结肠癌检测产品中的应用 |
| WO2024206495A2 (en) * | 2023-03-27 | 2024-10-03 | Immunis.Ai, Inc. | Active surveillance and risk stratification for prostate cancer |
| CN119372311A (zh) * | 2024-09-30 | 2025-01-28 | 东南大学 | 基于成纤维细胞相关基因的结肠癌预后和治疗抵抗预测模型的构建方法和应用 |
| CN120009551B (zh) * | 2025-02-27 | 2025-08-15 | 西南医科大学 | 剪接因子wbp11及其抑制剂的用途、预防或治疗结直肠癌的药物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7695913B2 (en) * | 2006-01-11 | 2010-04-13 | Genomic Health, Inc. | Gene expression markers for colorectal cancer prognosis |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU575586B2 (en) | 1983-09-02 | 1988-08-04 | Syngene, Inc. | Oligonucleotide synthesis employing primer with oxidzable substituents in system |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| JP2955759B2 (ja) | 1988-07-20 | 1999-10-04 | セゲブ・ダイアグノスティックス・インコーポレイテッド | 核酸配列を増幅及び検出する方法 |
| US5219727A (en) | 1989-08-21 | 1993-06-15 | Hoffmann-Laroche Inc. | Quantitation of nucleic acids using the polymerase chain reaction |
| US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
| US5554501A (en) | 1992-10-29 | 1996-09-10 | Beckman Instruments, Inc. | Biopolymer synthesis using surface activated biaxially oriented polypropylene |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| DE69503126T2 (de) | 1994-05-05 | 1998-11-12 | Beckman Instruments Inc | Repetitive oligonukleotide matrix |
| WO1996002668A1 (en) | 1994-07-15 | 1996-02-01 | Azco Nobel N.V. | Use of rna polymerase to improve nucleic acid amplification process |
| AT402203B (de) | 1995-06-13 | 1997-03-25 | Himmler Gottfried Dipl Ing Dr | Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren |
| US5716784A (en) | 1996-02-05 | 1998-02-10 | The Perkin-Elmer Corporation | Fluorescence detection assay for homogeneous PCR hybridization systems |
| EP2369007B1 (en) | 1996-05-29 | 2015-07-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US5985567A (en) | 1997-08-15 | 1999-11-16 | Beckman Coulter, Inc. | Hybridization detection by pretreating bound single-stranded probes |
| US6013789A (en) | 1998-02-20 | 2000-01-11 | Beckman Coulter, Inc. | Covalent attachment of biomolecules to derivatized polypropylene supports |
| AU2001252945A1 (en) | 2000-03-24 | 2001-10-08 | Corixa Corporation | Compositions and methods for therapy and diagnosis of colon cancer |
| US20060046249A1 (en) | 2002-01-18 | 2006-03-02 | Fei Huang | Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US20040146921A1 (en) | 2003-01-24 | 2004-07-29 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
| US20050287544A1 (en) * | 2003-12-01 | 2005-12-29 | Francois Bertucci | Gene expression profiling of colon cancer with DNA arrays |
| JP2008504803A (ja) * | 2004-01-09 | 2008-02-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 遺伝子発現の細胞型特異的パターン |
| US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
| WO2005083128A2 (en) | 2004-02-25 | 2005-09-09 | University Of South Florida | Methods for predicting cancer outcome and gene signatures for use therein |
| JP2008504018A (ja) | 2004-06-03 | 2008-02-14 | ジョンズ ホプキンス ユニバーシティ | 細胞増殖または新生物性障害に関してスクリーニングする方法 |
| AU2005300688B2 (en) | 2004-11-03 | 2012-02-02 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
| TW200730825A (en) * | 2005-10-21 | 2007-08-16 | Genenews Inc | Method and apparatus for correlating levels of biomarker products with disease |
| WO2007112330A2 (en) | 2006-03-24 | 2007-10-04 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of colon cancer |
| US20100261169A1 (en) * | 2007-01-29 | 2010-10-14 | Shira Wallach | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| WO2009147537A2 (en) | 2008-05-27 | 2009-12-10 | Dako Denmark A/S | Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers |
| WO2010060055A1 (en) | 2008-11-21 | 2010-05-27 | Duke University | Predicting cancer risk and treatment success |
-
2012
- 2012-01-25 AU AU2012209074A patent/AU2012209074A1/en not_active Abandoned
- 2012-01-25 JP JP2013551314A patent/JP2014509189A/ja active Pending
- 2012-01-25 MX MX2013008367A patent/MX2013008367A/es unknown
- 2012-01-25 EA EA201391074A patent/EA201391074A1/ru unknown
- 2012-01-25 CN CN201280010123.2A patent/CN103403543B9/zh not_active Expired - Fee Related
- 2012-01-25 SG SG2013056254A patent/SG192108A1/en unknown
- 2012-01-25 US US13/981,601 patent/US10196691B2/en not_active Expired - Fee Related
- 2012-01-25 CA CA2825218A patent/CA2825218A1/en not_active Abandoned
- 2012-01-25 WO PCT/US2012/022594 patent/WO2012103250A2/en not_active Ceased
- 2012-01-25 EP EP12739742.0A patent/EP2668296B1/en not_active Not-in-force
- 2012-01-25 BR BR112013018924A patent/BR112013018924A2/pt not_active IP Right Cessation
- 2012-01-25 KR KR1020137021973A patent/KR20140006898A/ko not_active Withdrawn
-
2013
- 2013-07-04 ZA ZA2013/05024A patent/ZA201305024B/en unknown
- 2013-07-24 IL IL227643A patent/IL227643A0/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7695913B2 (en) * | 2006-01-11 | 2010-04-13 | Genomic Health, Inc. | Gene expression markers for colorectal cancer prognosis |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2668296A4 (en) | 2015-09-02 |
| CN103403543B (zh) | 2016-11-09 |
| AU2012209074A1 (en) | 2013-07-11 |
| EA201391074A1 (ru) | 2013-12-30 |
| IL227643A0 (en) | 2013-09-30 |
| US10196691B2 (en) | 2019-02-05 |
| BR112013018924A2 (pt) | 2018-05-08 |
| SG192108A1 (en) | 2013-08-30 |
| ZA201305024B (en) | 2014-03-26 |
| WO2012103250A3 (en) | 2012-10-11 |
| EP2668296B1 (en) | 2018-08-15 |
| EP2668296A2 (en) | 2013-12-04 |
| US20140094379A1 (en) | 2014-04-03 |
| JP2014509189A (ja) | 2014-04-17 |
| CA2825218A1 (en) | 2012-08-02 |
| CN103403543A (zh) | 2013-11-20 |
| MX2013008367A (es) | 2013-08-12 |
| KR20140006898A (ko) | 2014-01-16 |
| NZ612471A (en) | 2015-11-27 |
| WO2012103250A2 (en) | 2012-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103403543B9 (zh) | 结肠癌基因表达签名及使用方法 | |
| Konstantinopoulos et al. | Gene expression profile of BRCA ness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer | |
| EP3435084B1 (en) | Prostate cancer prognostics using biomarkers | |
| KR101504817B1 (ko) | 국소 진행형 위암에 대한 예후 예측 시스템 | |
| Waddell et al. | Gene expression profiling of formalin‐fixed, paraffin‐embedded familial breast tumours using the whole genome‐DASL assay | |
| KR20150100698A (ko) | 갑상선 종양을 진단하기 위한 조성물 및 방법 | |
| CA2859663A1 (en) | Identification of multigene biomarkers | |
| CN104603292A (zh) | 用于提供前列腺癌的临床评估的方法、试剂盒和组合物 | |
| EP2419540B1 (en) | Methods and gene expression signature for assessing ras pathway activity | |
| EP2665835B1 (en) | Prognostic signature for colorectal cancer recurrence | |
| CA2596640A1 (en) | Methods of predicting chemotherapy responsiveness in breast cancer patients | |
| CN104031915A (zh) | 用于结直肠癌预后的基因片段及其应用 | |
| WO2013109613A1 (en) | Gene signature is associated with early stage rectal cancer recurrence | |
| US20190024184A1 (en) | Distinguishing metastatic-lethal prostate cancer from indolent prostate cancer using methylation status of epigenetic markers | |
| US20250191759A1 (en) | Breast Cancer Diagnostic and Treatment | |
| WO2021003176A1 (en) | Identification of patients that will respond to chemotherapy | |
| WO2020251645A1 (en) | 7-gene prognostic and predictive assay for non-small cell lung cancer in formalin fixed and paraffin embedded samples | |
| CN114901836B (zh) | 肝移植的临床和分子预后标志物 | |
| US20250034648A1 (en) | Kits and methods useful for prognosing, diagnosing, and treating prostate cancer | |
| CN110004230A (zh) | 一种用于乳腺癌诊断的lncRNA标志物 | |
| WO2024145266A1 (en) | Compositions and methods for diagnosing early-stage colorectal adenomas or cancers | |
| NZ612471B2 (en) | Colon cancer gene expression signatures and methods of use | |
| CN117568482A (zh) | 用于胃癌预后的分子标记物及其应用 | |
| HK1191675A (en) | Prognostic signature for colorectal cancer recurrence | |
| HK1231515A1 (en) | Gene expression panel for prognosis of prostate cancer recurrence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CI03 | Correction of invention patent | ||
| CI03 | Correction of invention patent |
Correction item: Claims Correct: Correct False: Error Number: 45 Page: full text Volume: 32 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161109 Termination date: 20200125 |